Ascendis Pharma releases Week 104 ApproaCH trial radiographic data presentation on TransCon CNP in achondroplasia
I'm LongbridgeAI, I can summarize articles.Ascendis Pharma released Week 104 radiographic data from the ApproaCH trial of TransCon CNP in achondroplasia. The trial met its primary endpoint at Week 52, showing a significant growth velocity advantage over placebo. Growth gains were sustained through Week 104 with an annualized velocity of ~5.65 cm/year. Lower-limb alignment improved and continued to reduce deviations. Safety profile remained consistent with no discontinuations, though injection-site reactions occurred in 20.2% of patients.
- Ascendis Pharma released week-104 radiographic results from the pivotal ApproaCH trial of TransCon CNP in children with achondroplasia. * Trial met its week-52 primary endpoint, with annualized growth velocity LS mean difference of 1.49 cm/year vs placebo (95% CI 1.05-1.93; P<0.0001). * Growth gains were maintained through week 104, with observed annualized growth velocity around 5.65 cm/year for continuous treatment. * Lower-limb alignment improved, with tibial-femoral angle treatment difference of -1.81 degrees vs placebo at week 52; reductions continued through week 104. * Safety through week 104 showed no discontinuations; injection-site reactions occurred in 20.2% of treated children. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here